Abstract:
Background: Potential benefits of drug-eluting balloons (DEBs) in patients suffered from in-stent restenosis was observed in international studies but data is lacking from Pakistan. Objective: Treatment and outcome of In-Stent restenosis with drug-eluting balloons: A real-life hospital-based study. Study Design: Descriptive cross-sectional. Settings: Department of intervention, national institute of cardiovascular diseases, Karachi & other satellite centers, Pakistan. Duration: Between the period of June 2022 and November 2022. Methods: A hospital-based clinical study in which 109 patients were included through a consecutive sampling technique. The eligibility criteria for patients inclusion was, all adult males and females, age =18 years, previously treated with a paclitaxel-eluting balloon, and consented to participate. Data were analyzed using SPSS version 26.0 and outcome (MACE, mortality, and TLR) were calculated. Results: The mean age of study participants was 53.27 ± 7.91 years. Majority of the patients were males (n = 72, 66.05%), urban dwellers (58.37%), and married (80.73%). Hypertension was the most common comorbid condition (38.53%). The most common indication was ISR-DES (74.31%, 81). Major adverse cardiovascular events and mortality rate were observed 7.33% and 12.84% vs. 2.75% and 6.42% at 3 and 6 months. Conclusion: Benefits of DEB in ISR have been observed in our study. MACE and mortality were observed less frequent. Patients should be considered for DEB in ISR.